Last updated: July 19, 2026
Antrim Pharms LLC operates as a contract manufacturer and/or product supplier across multiple generic and branded-to-generic transition opportunities, with its competitive posture driven by two factors: (1) whether its products are protected by identifiable, enforceable US patents or FDA exclusivities listed in the Orange Book; and (2) whether its pipeline and manufacturing footprint line up with time-to-market windows created by patent expirations, Paragraph IV litigation, and settlement-triggered launch dates. Without a drug-level scope (specific NDA/ANDA/BLA products), a complete patent estate and exclusivity timeline cannot be mapped to market position.
What products does Antrim Pharms LLC sell in the US and who competes with it?
No product list, FDA application linkage, or Orange Book entry set is provided. Without identified marketed drug labels (NDA/ANDA numbers) and corresponding FDA registration/labeler data, competitive analysis cannot be tied to actual therapeutic incumbents, authorized generics, or biosimilar cohorts.
How do competitors map by therapeutic class if Antrim Pharms LLC is a contract manufacturer?
Contract manufacturing competition depends on the following, none of which is specified:
- Which active ingredients and dosage forms Antrim supplies (tablets, capsules, injectables, creams, inhalation).
- Whether Antrim is a sponsor/holder (applicant) of ANDAs or a manufacturing-only vendor.
- Whether products are “first-to-file” ANDAs facing forfeiture risks or later entries facing carve-outs.
How strong is the patent estate around Antrim Pharms LLC’s portfolio?
No portfolio claims, listed patents, patent expiration dates, or Orange Book entries are included. Patent strength analysis requires mapping each relevant FDA application to:
- Orange Book listed patents (composition of matter, formulation, method of use, manufacturing process).
- Expiration and pediatric exclusivity (if applicable).
- Any PTA and extension effects.
- Whether patents are associated with FDA exclusivities (5-year NCE, 3-year new clinical investigations, 7-year orphan, RLD exclusivity).
When do key exclusivities and patents expire for Antrim Pharms LLC products?
No specific products, NDA/ANDA numbers, or patent expiry dates are provided. A timeline cannot be constructed for exclusivity loss, generic launch windows, or settlement-driven “no earlier than” dates.
What patents protect the active ingredients and formulations used by Antrim Pharms LLC?
A formulation and process patent map requires identification of:
- Each active ingredient (INN/USAN).
- The dosage form (immediate release, extended release, film-coated, transdermal, lyophilized, etc.).
- The proprietary formulation or manufacturing steps that would trigger US patent listings.
No such drug/formulation identifiers are supplied.
What patent litigation affects Antrim Pharms LLC generic entry risk (Paragraph IV and settlements)?
Paragraph IV risk depends on:
- Specific ANDA applications filed against listed Orange Book patents for a given reference listed drug (RLD).
- The siting of litigation in the US District Court and the linkage to the FDA application.
- Settlement terms affecting launch (“carve-out,” “60-month stay,” “licensed-to-settle,” or “no-early-launch”).
No litigation docket or ANDA/REMS/applicant mapping is included.
What is the Orange Book status of Antrim Pharms LLC products (listed patents, patent types, exclusivity)?
Orange Book status is application-specific. Without the relevant NDA/ANDA identifiers, it is not possible to enumerate:
- Listed patents and their patent numbers.
- Patent type codes and scope.
- Expiration dates and remaining terms.
How does Antrim Pharms LLC compare with major generic manufacturers in the same therapeutic areas?
Comparison requires:
- Overlapping product sets and therapeutic classification.
- Market entry timing.
- Pricing and reimbursement position.
None of these inputs are provided.
What launch strategy would a generic competitor use against Antrim Pharms LLC?
A competitor’s strategy would depend on whether Antrim’s products are:
- RLD-replacement generics with nontrivial process/formulation differentiation.
- “Authorized” generics with licensing constraints.
- Late-cycle products facing low patent friction.
No Antrim product launch dates or patent friction points are provided.
What generic entry risks exist for Antrim Pharms LLC (ANDA-to-ANDA and authorized generic challenges)?
Entry risks by type require a portfolio map:
- ANDA-to-ANDA competition once exclusivity ends.
- Authorized generic arrangements that block or delay certain entrants.
- 180-day exclusivity holders and forfeiture triggers.
No application or exclusivity holder data is provided.
What manufacturing and IP barriers could limit Antrim Pharms LLC capacity expansion?
A barrier analysis requires:
- Drug product dosage forms (sterile vs non-sterile).
- Facility status under FDA inspections and quality agreements.
- Process patents (capsule fill, compression conditions, coating processes, sterile filling aseptic parameters).
No manufacturing footprint or drug product categories are provided.
What regulatory pathway issues matter for Antrim Pharms LLC (ANDA, 505(b)(2), 3-year/5-year exclusivity)?
Regulatory analysis requires identifying:
- Whether products are ANDA (generic) or 505(b)(2) hybrids.
- Whether the reference product has NCE or 505(b)(2) exclusivity blocking certain submissions.
- Bioequivalence approach and any clinical superiority requirements.
No FDA pathway details are supplied.
How many patents cover Antrim Pharms LLC active ingredients, and how are they distributed?
A “count” analysis requires explicit patent lists per FDA application:
- Composition of matter: highest litigation risk if broad.
- Formulation: common for sustained release, taste-masking, solubility systems.
- Method of use: depends on approved indications and carve-outs.
- Manufacturing/process: common for complex drug delivery or sterile products.
No patent lists are provided.
Key Takeaways
- A complete competitive landscape for Antrim Pharms LLC requires a drug-level mapping to FDA applications (NDA/ANDA/BLA) and associated Orange Book patents and FDA exclusivities. Those identifiers are not present.
- Market-position and strength cannot be quantified without the specific portfolio and the patent estate per product, including litigation status and settlement-driven launch constraints.
- Any attempt to model generic entry risk, biosimilar risk, or exclusivity timelines would be non-actionable without product identifiers.
FAQs
- How is Paragraph IV litigation risk determined for an ANDA sponsor when the Orange Book lists both formulation and method-of-use patents?
- What does “authorized generic” typically change in the competitive landscape for generic entrants versus the 180-day exclusivity holder?
- How do pediatric exclusivity and patent term adjustment change the timing of generic launch windows?
- When do process patents (manufacturing method) remain enforceable after generic approval, and how do they affect design-around strategies?
- How do facility sterility requirements and aseptic processing constraints translate into IP and regulatory barriers for dosage-form expansion?
References
No sources were provided or can be cited from the prompt.
